Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   26/03/2026
191,06 USD (+0,99%)
(+0,99%)   26/03/2026
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

20 maart 2026 · Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 · Persbericht

19 maart 2026 · Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting · Persbericht

11 maart 2026 · Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy · Persbericht

5 maart 2026 · Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences · Persbericht

4 maart 2026 · The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome · Persbericht

11 februari 2026 · Biogen Announces Board Chair Transition · Persbericht

4 februari 2026 · Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy · Persbericht

28 januari 2026 · Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options · Persbericht

26 januari 2026 · FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review · Persbericht

12 januari 2026 · Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties